The Current Practice of Theranostics: Results of a National Survey and Lessons Learned
Journal of Nuclear Medicine Technology · 2025-12 · 53 (Supplement 1) · 4S-12S
DOI: 10.2967/jnmt.125.270826 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Nuclear Medicine Technology, online erschienen am 04.12.2025. Verfasst von Victoria West und 6 weiteren Autor:innen. Beteiligte Einrichtung: Molecular Imaging and Therapy, Oregon Health & Science University, Portland, Oregon westv@ohsu.edu. Hauptthemen laut MEDLINE: Theranostic Nanomedicine. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 32 Literaturangaben.
Abstract (Originalsprache)
Theranostic programs are expanding rapidly, creating a growing need to understand how institutions implement [177Lu]Lu-DOTATATE therapy and [177Lu]Lu-PSMA-617 therapy in clinical practice.
Methods
We distributed a 25-question online survey to U.S. health care institutions that administer 177Lu therapies. The survey collected data on therapy administration, patient monitoring, imaging protocols, and radiation safety practices.
Results
Thirty-five institutions responded. Practices varied widely in administration methods, vital sign monitoring, antiemetic use, and imaging protocols. Most sites infused [177Lu]Lu-DOTATATE over an average of 30 min via pump or gravity method, whereas [177Lu]Lu-PSMA-617 was more often administered by hand injection within 10 min. Vital signs were monitored at 91% of [177Lu]Lu-DOTATATE therapy sites compared with 57% for [177Lu]Lu-PSMA-617 therapy. Antiemetics were used at 97% of [177Lu]Lu-DOTATATE sites versus 23% at [177Lu]Lu-PSMA-617 sites. Posttherapy imaging was performed for 48% of [177Lu]Lu-DOTATATE therapies and 57% of [177Lu]Lu-PSMA-617 therapies, with substantial variation in timing and frequency.
Conclusion
These results indicate significant variability in clinical theranostics practice in the United States and may result in meaningful differences in patient outcomes and satisfaction. The findings emphasize the necessity for consensus guidelines and standardization. This article also explores key lessons learned from real-world implementation, highlighting the evolving nature of theranostic programs as they expand in clinical practice.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Molecular Imaging and Therapy, Oregon Health & Science University, Portland, Oregon westv@ohsu.edu.
- Molecular Imaging and Therapy, Oregon Health & Science University, Portland, Oregon.
Zitieren
APA
West, V., Morse, P., Nguyen, M., Ali, R., Mallak, N., Winters, C., & Mittra, E. (2025). The Current Practice of Theranostics: Results of a National Survey and Lessons Learned. Journal of Nuclear Medicine Technology, 53(Supplement 1), 4S-12S. https://doi.org/10.2967/jnmt.125.270826
Vancouver
West V, Morse P, Nguyen M, Ali R, Mallak N, Winters C, et al. The Current Practice of Theranostics: Results of a National Survey and Lessons Learned. Journal of Nuclear Medicine Technology. 2025;53(Supplement 1):4S-12S. doi:10.2967/jnmt.125.270826
BibTeX
@article{West2025,
author = {West, Victoria and Morse, Phillip and Nguyen, Mike and Ali, Razan and Mallak, Nadine and Winters, Celeste and Mittra, Erik},
title = {The Current Practice of Theranostics: Results of a National Survey and Lessons Learned},
journal = {Journal of Nuclear Medicine Technology},
year = {2025},
volume = {53},
number = {Supplement 1},
pages = {4S--12S},
doi = {10.2967/jnmt.125.270826}
}
EUVIMED